

Lenvima Approval Status Worldwide (Country/ Region)

June, 2020

Thyroid cancer

Argentina	May-2019	Hong Kong	May-2016	Myanmar	Nov-2018	Switzerland	Aug-2015
Australia	Jan-2016	Hungary	May-2015	Netherlands	May-2015	Taiwan	Sep-2016
Austria	May-2015	Iceland	May-2015	New Zealand	Apr-2020	Thailand	Mar-2016
Bahrain	Dec-2020	India	Jan-2017	Norway	May-2015	UAE	Feb-2017
Belgium	May-2015	Indonesia	Jul-2018	Panama	Mar-2020	UK	May-2015
Brazil	Aug-2016	Ireland	May-2015	Peru	May-2019	US	Feb-2015
Brunei	Dec-2018	Israel	Jan-2016	Philippines	Dec-2016		
Bulgaria	May-2015	Italy	May-2015	Poland	May-2015		
Cambodia	Apr-2019	Japan	Mar-2015	Portugal	May-2015		
Canada	Dec-2015	Jordan	Nov-2019	Romania	May-2015		
Chile	Jul-2019	Kuwait	May-2016	Russia	Dec-2015		
Croatia	May-2015	Latvia	May-2015	Saudi Arabia	Dec-2019		
Cyprus	May-2015	Lebanon	Nov-2016	Singapore	Apr-2016		
Czech Republic	May-2015	Liechtenstein	May-2015	Slovakia	May-2015		
Denmark	May-2015	Lithuania	May-2015	Slovenia	May-2015		
Estonia	May-2015	Luxembourg	May-2015	South Africa	May-2020		
Finland	May-2015	Macau	Sep-2015	South Korea	Oct-2015		
France	May-2015	Malaysia	Nov-2016	Spain	May-2015		
Germany	May-2015	Malta	May-2015	Sri Lanka	Feb-2019		
Greece	May-2015	Mexico	May-2016	Sweden	May-2015		

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

2nd line Renal cell carcinoma

Argentina	May-2019	Iceland	Aug-2016	Philippines	Dec-2016
Australia	Jul-2017	India	Dec-2019	Poland	Aug-2016
Austria	Aug-2016	Ireland	Aug-2016	Portugal	Aug-2016
Belgium	Aug-2016	Israel	Dec-2016	Romania	Aug-2016
Brazil	Oct-2018	Italy	Aug-2016	Russia	Sep-2016
Brunei	Dec-2018	Latvia	Aug-2016	Singapore	May-2017
Bulgaria	Aug-2016	Lebanon	May-2017	Slovakia	Aug-2016
Canada	Sep-2017	Liechtenstein	Aug-2016	Slovenia	Aug-2016
Chile	Jul-2019	Lithuania	Aug-2016	South Africa	May-2020
Croatia	Aug-2016	Luxembourg	Aug-2016	Spain	Aug-2016
Cyprus	Aug-2016	Macau	Jul-2018	Sri Lanka	Feb-2019
Czech Republic	Aug-2016	Malaysia	Oct-2018	Sweden	Aug-2016
Denmark	Aug-2016	Malta	Aug-2016	Switzerland	Aug-2017
Estonia	Aug-2016	Mexico	Jan-2018	Taiwan	Jul-2017
Finland	Aug-2016	Myanmar	Jun-2019	Thailand	Mar-2018
France	Aug-2016	Netherlands	Aug-2016	UK	Aug-2016
Germany	Aug-2016	New Zealand	Apr-2020	US	May-2016
Greece	Aug-2016	Norway	Aug-2016		
Hong Kong	Nov-2017	Panama	Mar-2020		
Hungary	Aug-2016	Peru	May-2019		

In Europe, lenvatinib is approved under the brand name Kisplyx[®] for treatment of renal cell carcinoma

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

Lenvima Approval Status Worldwide (Country/ Region)

June, 2020

Hepatocellular carcinoma

Argentina	May-2019	Hungary	Aug-2018	Panama	Mar-2020	UK	Aug-2018
Australia	Sep-2018	Iceland	Aug-2018	Peru	May-2019	US	Aug-2018
Austria	Aug-2018	India	Mar-2019	Philippines	Oct-2018		
Bahrain	May-2020	Indonesia	Nov-2019	Poland	Aug-2018		
Belgium	Aug-2018	Ireland	Aug-2018	Portugal	Aug-2018		
Brazil	Feb-2019	Israel	Apr-2019	Romania	Aug-2018		
Bulgaria	Aug-2018	Italy	Aug-2018	Russia	Oct-2018		
Canada	Dec-2018	Japan	Mar-2018	Saudi Arabia	May-2020		
China	Sep-2018	Latvia	Aug-2018	Singapore	May-2019		
Chile	Jul-2019	Lebanon	Feb-2019	Slovakia	Aug-2018		
Croatia	Aug-2018	Liechtenstein	Aug-2018	Slovenia	Aug-2018		
Cyprus	Aug-2018	Lithuania	Aug-2018	South Africa	May-2020		
Czech Republic	Aug-2018	Luxembourg	Aug-2018	South Korea	Aug-2018		
Denmark	Aug-2018	Macau	Apr-2019	Spain	Aug-2018		
Estonia	Aug-2018	Malaysia	Nov-2019	Sri Lanka	Feb-2019		
Finland	Aug-2018	Malta	Aug-2018	Sweden	Aug-2018		
France	Aug-2018	Myanmar	Oct-2019	Switzerland	Oct-2018		
Germany	Aug-2018	Netherlands	Aug-2018	Taiwan	Nov-2018		
Greece	Aug-2018	New Zealand	Apr-2020	Thailand	May-2019		
Hong Kong	Feb-2019	Norway	Aug-2018	UAE	Jun-2019		

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

2nd line Endometrial Carcinoma(EC)

Australia	Sep-2019
Canada	Sep-2019
Philippines	Mar-2020
South Korea	May-2020
US	Sep-2019

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.